Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have non-small cell lung cancer that is not of the squamous type (mixed types allowed if the main part is adenocarcinoma).
- Your cancer must be stage IIIB, IIIC, or IV, or have returned (recurrent) and cannot be treated with surgery or radiation.
- You must not have previously received EGFR inhibitor drugs or other systemic treatments for advanced stages of your lung cancer.
- Your tumor must have a specific EGFR mutation (either Ex19del or L858R).
- You must provide a tumor tissue sample for testing.
- You must have a good performance status (able to carry out daily activities).
- You must have at least one measurable tumor that has not been previously treated with radiation.
- Your bone marrow and organ function must be adequate.
- You must not have serious or uncontrolled medical conditions, including active bleeding.
- You must not have a history of another primary cancer.
- You must not have spinal cord compression or unstable brain metastases.
- You must not have clinically significant corneal disease.
- You must not have active or uncontrolled hepatitis B or C infection.
- You must not have a history of interstitial lung disease (ILD) or drug-induced ILD, or suspected ILD that cannot be ruled out by imaging.
- You must not have severely reduced lung function due to other lung diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a combination of two drugs, osimertinib and etoposide, for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding well to osimertinib alone. It may help if your cancer is stable or slowly getting worse on osimertinib as your first treatment.
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
This trial tests a combination of two targeted drugs (osimertinib and dalpiciclib) for people with advanced lung cancer whose tumors have a specific EGFR mutation and a change in the CDK4/6 pathway, and whose cancer has stopped responding to a third-generation EGFR targeted therapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.